Dry Eye Syndrome ("Dry Eye")

Multifactorial disease of the tear and ocular surface resulting in discomfort, visual disturbance and tear film instability with potential damage to the ocular surface.*

  • Tear layer protects the surface of the eye, providing nutrition

  • Injury is a dynamic process, resulting in change in tear composition & symptoms of burning, redness, blurred vision, etc.

  • Dry Eye is the most frequent symptom treated by ophthalmologists

  • Epidemiological studies show dry eye will occur in 14-33% of population. Market size in 2014 est. + $2.5B, increasing steadily every year. 

  • Increase in incidence with age and other factor

Conjunctivochalasis (CCh)

  • Conjunctivochalasis (CCh) is a complication of dry eye

  • Aseptic, chronic inflammation of the conjunctiva; on a background of dry eye syndrome

  • Common age-related eye condition over 50; increases in frequency &  severity with age

  • Also markedly increased in people wearing contact lenses, regardless of age

  • Appears in one third of dry eye patients

  • Inflammation condition is sustained; not spontaneously reversible

  • Severe CCh (Stage 3) can only be treated by invasive surgical treatment, which can cause considerable discomfort

Sjögren’s Syndrome

  • Sjögren’s syndrome is a chronic long-term auto-immune disease

  • The patient's white blood cells attack the saliva and tear glands, leading to dry mouth and eyes

  • While Sjögren’s syndrome can develop at any age, the majority of patients are diagnosed after the age of 40 with 90% of patients female

  • There are approximately 4,000,000 people in the USA and 500,000 in the UK with Sjögren’s Syndrome

© 2017 by Wize Pharma Inc. All Rights Reserved.